Claims for Patent: 8,685,394

Summary for Patent: 8,685,394

Title:	Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.
Inventor(s):	Jure-Kunkel; Maria (Plainsboro, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	13/384,900
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,685,394
Patent Claims:	1. A method for the treatment of cancer, consisting of the administration to a mammal in need thereof a synergistic, therapeutically effective amount of an anti-CTLA-4 antibody, in addition to one or more diluents, vehicles, excipients, and/or inactive ingredients, at a dose ranging from about 3 mg/kg to about 10 mg/kg; with the chemotherapeutic agent 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-.beta.-D-glucopyranoside], 4'-(dihydrogen phosphate), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, at a dose of 100 mg/kg; wherein said treatment is sufficient to synergistically reduce tumor burden, produce tumor regression, or reduce tumor development of said cancer. 2. The method according to claim 1 wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab. 3. The method according to claim 1, wherein said anti-CTLA-4 antibody is ipilimumab. 4. The method according to claim 1, wherein said cancer is a solid tumor. 5. The method according to claim 4, wherein said solid tumor is selected from the group consisting of: lung cancer, sarcoma, fibrosarcoma, pancreatic cancer, prostate cancer, and colon cancer. 6. The method according to claim 1, wherein said method is for the treatment of a tumor refractory to said chemotherapeutic agent. 7. The method according to claim 1, wherein said chemotherapeutic agent is administered before the administration of said anti-CTLA4 antibody. 8. The method according to claim 1, wherein said chemotherapeutic agent is administered essentially simultaneously with the administration of said anti-CTLA4 antibody. 9. The method according to claim 1, wherein said chemotherapeutic agent is administered daily. 10. The method according to claim 1, wherein said anti-CTLA4 antibody is administered about every three weeks.

Details for Patent 8,685,394

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2028-08-01